Corporate Deals, Investments & Strategic Moves
Honeywell (HON) announced its acquisition of Johnson Matthey’s Catalyst Technologies business, bolstering its advanced technology portfolio. Read more.
KLA (KLAC) expanded its operations in Wales with a US$138 million R&D and manufacturing facility, reinforcing its leadership in semiconductor innovation. Read more.
Newmark (NMRK) facilitated a US$7.1 billion construction loan for an AI data center, merging real estate finance with cutting‐edge technology. Read more.
Kingstone (KINS) successfully sponsored its inaugural US$125 million catastrophe bond, underscoring its confidence in risk management and capital strategies. Read more.
Goodyear (GT) revealed plans to sell its chemical business as part of a broader restructuring to sharpen its core focus. Read more.
Sanofi (SNY) opened new, US$130 million offices in Morristown, NJ, showcasing modern design and strengthening its US presence. Read more.
Financial Results & Market Performance
Ralph Lauren (RL) reported strong fourth quarter and full‐year fiscal 2025 results, reinforcing its standing in the luxury retail segment. Read more.
Intuit (INTU) delivered robust third‐quarter figures and raised their full‐year guidance, reflecting sustained growth in financial software solutions. Read more.
AUTODESK, INC. (ADSK) announced its fiscal 2026 first quarter results, indicating steady momentum in design and engineering software demand. Read more.
Workday (WDAY) posted strong fiscal 2026 first quarter financials, highlighting the strength of its enterprise cloud applications. Read more.
Deckers Brands (DECK) released its fourth quarter and full fiscal year 2025 results, showcasing resilient brand performance in a competitive market. Read more.
Copart (CPRT) announced its third quarter fiscal 2025 results, a key indicator of performance in the auto auction industry. Read more.
Strategy (MSTR) unveiled a US$2.1 billion at‐the‐market program, positioning the company for enhanced strategic investments and liquidity management. Read more.
FX Spot+ (CME) recorded an impressive US$1.4 billion in trades in a single day, highlighting vibrant market liquidity and trading activity. Read more.
Healthcare & Pharma Developments
Astellas and Pfizer (ALPMY) reported that XTANDI™ (enzalutamide) demonstrated long‐term overall survival benefits in metastatic hormone‐sensitive prostate cancer, marking a pivotal advancement in patient outcomes. Read more.
Regeneron (REGN) revealed that linvoseltamab in combination with carfilzomib or bortezomib is showing promising initial results in earlier treatment lines for relapsed/refractory multiple myeloma. Read more.
Verastem Oncology (VSTM) announced positive updated results from the RAMP 205 trial, where its combination therapy delivered encouraging activity in frontline metastatic pancreatic ductal adenocarcinoma. Read more.
Candel Therapeutics (CADL) presented positive Phase 3 CAN-2409 results in localized prostate cancer at ASCO 2025, further solidifying its developmental pipeline. Read more.
Exact Sciences (EXAS) highlighted innovations in early cancer detection and precision oncology at the 2025 ASCO Annual Meeting, underscoring breakthrough advancements in screening practices. Read more.
Legend Biotech (LEGN) announced new oncologic and hematologic therapeutic developments at ASCO, EHA, and ASGCT, reflecting its expanding role in cancer treatment innovation. Read more.
Exelixis (EXEL) reported encouraging results from the Phase 1b/2 STELLAR-002 trial evaluating Zanzalintinib with immune checkpoint inhibitors for advanced kidney cancer at ASCO 2025. Read more.
Allogene Therapeutics (ALLO) announced the ASCO 2025 abstract publication featuring an oral presentation of ALLO-316 in kidney cancer alongside the ALPHA3 TIP poster for Cema-Cel, emphasizing its innovative approach. Read more.
Merus (MRUS) presented interim data demonstrating robust efficacy and durability of petosemtamab combined with pembrolizumab in first‐line PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma. Read more.
Kura Oncology (KURA) and Kyowa Kirin announced pivotal monotherapy data for Ziftomenib via an oral presentation at the 2025 ASCO Annual Meeting, signifying a potential shift in therapeutic strategy. Read more.
Iovance (IOVA) announced five‐year results of Amtagvi® (lifileucel) in patients with advanced melanoma at the ASCO Annual Meeting, reinforcing its commitment to breakthroughs in immuno-oncology. Read more.
